Novo Nordisk A/S’s Return on Assets at a glance
Novo Nordisk A/S reports return on assets of 21.7% for Dec 2024. The prior period recorded 26.6% (Dec 2023). Year over year the metric moved −4.9 pts (−18.5%). The rolling three-period average stands at 23.8%. Data last refreshed Dec 7, 2025, 2:51 AM.
Latest reading
21.7% · Dec 2024
YoY movement
−4.9 pts (−18.5%)
Rolling average
23.8%
Current Return on Assets
21.7%
−4.9 pts
−18.5%
Rolling average
23.8%
Latest Value
21.7%
Dec 2024
YoY Change
−4.9 pts
Absolute
YoY Change %
−18.5%
Rate of change
3-Period Avg
23.8%
Smoothed
Narrative signal
Novo Nordisk A/S’s return on assets stands at 21.7% for Dec 2024. Year-over-year, the metric shifted by −4.9 pts, translating into a −18.5% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How return on assets shapes Novo Nordisk A/S's story
As of Dec 2024, Novo Nordisk A/S reports return on assets of 21.7%. Track return on assets to gauge balance sheet efficiency, asset intensity, and capital deployment versus peers.
Asset efficiency signal
Higher ROA indicates management is generating greater profit from the asset base. Watch for multi-year trends and industry benchmarks.
Use with leverage metrics
Compare ROA with ROE to understand how leverage magnifies returns on equity versus returns produced by total assets.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Novo Nordisk A/S (NVO) FAQs
Answers tailored to Novo Nordisk A/S’s return on assets profile using the latest Financial Modeling Prep data.
What is Novo Nordisk A/S's current return on assets?
As of Dec 2024, Novo Nordisk A/S reports return on assets of 21.7%. This reading reflects the latest filings and price data for NVO.
How is Novo Nordisk A/S's return on assets trending year over year?
Year-over-year, the figure shifts by −4.9 pts (−18.5%). Pair this context with revenue growth and free cash flow signals to gauge momentum for NVO.
Why does return on assets matter for Novo Nordisk A/S?
Return on assets measures how efficiently a company turns average assets into net income. For Novo Nordisk A/S, operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Novo Nordisk A/S's return on assets above its recent average?
Novo Nordisk A/S's rolling three-period average sits at 23.8%. Comparing the latest reading of 21.7% to that baseline highlights whether momentum is building or fading for NVO.
How frequently is Novo Nordisk A/S's return on assets refreshed?
Data for NVO was last refreshed on Dec 7, 2025, 2:51 AM and updates automatically every 24 hours, keeping your valuation inputs current.